34例淋巴瘤骨髓浸润患者治疗与预后分析  

Study on the treatment and prognosis of 34 lymphoma patients with bone marrow infiltration

作　　者：马静秋[1] 梁辉[1] 董戴玉[1] 严云[1] 卞锦国[1] 杨镜明[1] 

机构地区：[1]上海第二医科大学新华医院血液科,上海200092

出　　处：《上海第二医科大学学报》2004年第5期343-344,378,共3页Acta Universitatis Medicinalis Secondae Shanghai

摘　　要：目的 探讨淋巴瘤骨髓浸润患者的治疗与预后。方法 34例淋巴瘤骨髓浸润患者分为单纯化疗组、化疗+放疗组、大剂量化疗+自体干细胞移植组进行治疗,长期随访,分析其预后状况。结果 全组中位生存期为20个月;1年和3年生存率分别为76.47％和26.47％,最初疗效为完全缓解和部分缓解患者的1年和3年生存率均大于未缓解患者(P<0.05);大剂量化疗+自体干细胞移植组的3年生存率大于单纯化疗组和化疗+放疗组(P<0.05)。结论 淋巴瘤骨髓浸润患者的生存率与最初疗效有关;大剂量化疗+自体干细胞移植能提高其生存率,改善预后。Objective To analyze the treatment and prognosis of lymphoma patients with bone marrow infiltration. Methods Thirty-four lymphoma patients with bone marrow infiltration were divided into three groups ( group chemotherapy , group chemotherapy and radiation therapy and group high dose chemotherapy ( HDC) with autologous stem cell transplantation). They were actively treated, long-term follow-up and analyzed. Results The median survival was 20 months. One-year and three-year survival rates were 76. 47% and 26. 47% . One-year and three-year survival rate of the patients completely and partly remitted in initial treatment were higher than those not remitted in initial treatment (P <0. 05). Three-year survival rate of the patients received HDC with autologous stem cell transplantation (ASCT) was higher than those received chemotherapy only and comprehensive therapy (P <0.05). Conclusion The survival rate of patients with bone marrow infiltration related to the initial curative effect. HDC + ASCT can raise the survival rate of patients.

关 键 词：淋巴瘤 骨髓浸润 预后 化学治疗 自体干细胞移植 放射治疗 

分 类 号：R733.1[医药卫生—肿瘤]